Chemed Corporation (NYSE:CHE) Q4 2025 Earnings Call Transcript

robot
Abstract generation in progress

Chemed Corporation discussed its Q4 2025 earnings, acknowledging that results for both its VITAS Healthcare and Roto-Rooter subsidiaries fell short of expectations. The company outlined strategies to improve performance in 2026, including rebalancing patient mix for VITAS to address Medicare Cap limitations and implementing lead generation and billing improvements for Roto-Rooter. Despite a challenging quarter, management expressed confidence in their 2026 guidance, expecting growth to be weighted towards the second half of the year.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin